Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: A population-based assessment

Infection Control and Hospital Epidemiology

Volumn 23, Issue 11, 2002, Pages 683-688

  Thomas, Ann R ^a   Cieslak, Paul R ^b   Strausbaugh, Larry J ^c   Fleming, David W ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Office of Disease Prevention and Epidemiology   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; DISEASE CONTROL; DRUG USE; HEALTH CARE POLICY; HOSPITAL INFECTION; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; PHARMACY; POPULATION RESEARCH; PRACTICE GUIDELINE; RISK ASSESSMENT; STRAIN DIFFERENCE;

EID: 0036846364     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/501994     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44(RR12):1-13.
2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover F. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136.
3. Rotun SS, McMath V, Schoonmaker D, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-149.
4. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
5. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999. MMWR 2000;48: 1165-1167.
6. Garrett DO, Jochimsen E, Murfitt K, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999;20:167-170.
7. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System report: Data summary from January 1990-May 1999. Am J Infect Control 1999;27:520-532.
8. Salemi C, Becker L, Morrissey R, Warmington J. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Clinical Performance and Quality Health Care 1998;6:12-16.
9. Wright SW, Wrenn KD. Appropriateness of vancomycin use in the emergency department. Ann Emerg Med 1998;32:531-536.
10. Evans ME, Kortas KJ. Vancomycin use in a university medical center: Comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol 1996;17:356-359.
11. Johnson SV, Hoey LL, Vance-Bryan K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995;15:579-585.
12. Beidas S, Khamesian M. Vancomycin use in a university medical center: Comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol 1996;17:773-774.
13. Kahyaoglu O, Akpinar M, Nolan B, Inoue S, Zureikat G, Kumar A. Vancomycin use and monitoring in pediatric patients in a community hospital. Infect Control Hosp Epidemiol 1998;19:299, 301. Letter.
14. Logsdon BA, Lee KR, Luedtke G, Barrett FF. Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria. Infect Control Hosp Epidemiol 1997;18:780-782.
15. Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:970-973.
16. Goeckner BJ, Hendershot E, Scott K, Drake M. A vancomycin monitoring program at a community hospital. Jt Comm J Qual Improv 1998;24: 379-385.
17. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157: 1132-1136.
18. Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-769.
19. Lipsky BA, Baker CA, McDonald LL, Suzuki NT. Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 1999;27:84-91.
20. Cieslak PR, Strausbaugh LJ, Fleming DW, Ling JM. Vancomycin in Oregon: Who's using it and why. Infect Control Hosp Epidemiol 1999; 20:557-560.
21. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020- 1025.
22. Belliveau PP, Rothman AL, Maday CE. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. Am J Health Syst Pharm 1996;53:1570-1575.
23. Shojania KG, Yokoe D, Platt R, Fiskio J, Ma'luf N, Bates DW. Reducing vancomycin use utilizing a computer guideline: Results of a randomized controlled trial. J Am Med Inform Assoc 1998;5:554-562.
24. Misan GM, Martin ED, Smith ER, Somogyi AA, Bartholomeusz RC, Bochner F. Drug utilization review in a teaching hospital: Experience with vancomycin. Eur J Clin Pharmacol 1990;39:457-461.
25. Singer MV, Haft R, Barlam T, Aronson M, Shafer A, Sands KE. Vancomycin control measures at a tertiary-care hospital: Impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248-253.
26. Briceland LL, Quintiliani R, Nightingale CH. Multidisciplinary cost-containment program promoting oral metronidazole for treatment of antibiotic-associated colitis. Am J Hosp Pharm 1988;45:122-125.